IP Library › Granted Patent US 12,590,189
Granted Patent B2
US 12,590,189 · App. 17/751,052 · Granted Mar 31, 2026

Processes and systems for preparing cellular or viral membranes and nanoparticles

Inventors: Weiwei Gao (La Jolla, CA); Che-Ming Jack Hu (Nangang District, TW)
Assignee: ARYTHA BIOSCIENCES, LLC
C08J3/12C12N5/0006C12N5/0087C12N5/0641B01D2315/16B82Y40/00C08J2367/04C08J2377/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,590,189
App. No.
17/751,052
Granted
Mar 31, 2026
Kind
B2
Abstract

The present invention relates to processes and systems for preparing nanoparticles, cellular or viral membranes and/or cellular or viral membrane coated nanoparticles using or comprising, inter alia, a multi-inlet vortexing reactor, tangential flow filtration (TFF) and/or a high shear fluid processor such as a microfluidizer (or a microfluidizer processor). The present invention also relates to the nanoparticles, cellular or viral membranes and/or cellular or viral membrane coated nanoparticles prepared by the present processes and systems, and the uses and/or applications of the nanoparticles, cellular or viral membranes and/or cellular or viral membrane coated nanoparticles.

Claims (29)

1 . A process for preparing a cellular or viral membrane, said process comprises:

1) lysing a cell, a cellular vesicle or a virus to obtain a composition comprising a cellular or viral membrane and a non-membrane cellular or viral moiety; and

2) subjecting said composition to tangential flow filtration (TFF) using a TFF filter device to separate said cellular or viral membrane from said non-membrane cellular or viral moiety, and

wherein said TFF is conducted:

using a feeding rate ranging about 0.1 mL/minute to about 1,000 mL/minute;

using a feeding pressure ranging from about 0.1 psi to about 100 psi;

using a retentate pressure ranging from about 0.1 psi to about 100 psi; and

within a time ranging from about 10 minutes to about 10 hours for one production batch; and

wherein said TFF filter device comprises a filtration membrane having a pore size ranging from about 1 nm to about 650 nm; and

wherein said TFF is used to remove from about 50% to about 99.9999% of said non-membrane cellular or viral moiety and/or an organic solvent.

2 . The process of claim 1 , wherein the cell, cellular vesicle or virus is lysed using a hypotonic treatment, sonication, shear force, or a nitrogen decompression chamber.

3 . The process of claim 1 , wherein in step 1), a cell or a cellular vesicle is lysed to obtain a composition comprising a cellular membrane and a non-membrane cellular moiety.

4 . The process of claim 1 , wherein the cell is a blood cell.

5 . The process of claim 4 , wherein the blood cell is a red blood cell, a white blood cell or a platelet.

6 . The process of claim 1 , wherein the cell or cellular vesicle is derived from a tumor cell, a cancer cell, an immune cell, a stem cell, an endothelial cell, an exosome, a secretory vesicle or a synaptic vesicle.

7 . The process of claim 1 , wherein the cellular membrane is a plasma membrane, an intracellular membrane, or a membrane of a cellular vesicle.

8 . The process of claim 1 , wherein the cellular membrane is a plasma membrane derived from a blood cell.

9 . The process of claim 1 , wherein the non-membrane cellular or viral moiety is selected from the group consisting of a cellular organelle, a viral particle and an aggregate or complex thereof.

10 . The process of claim 1 , wherein the TFF is conducted using a TFF system that comprises a feed reservoir, a filter device and a collection device, the feed reservoir is in fluid communication with the filter device via an inlet on the filter device, the filter device is in fluid communication with the collection device via a permeate outlet on the filter device, and the filter device is in fluid communication with the feed reservoir via a retentate outlet on the filter device.

11 . The process of claim 1 , wherein the TFF is conducted via a diafiltration process.

12 . The process of claim 1 , wherein the TFF is conducted using a feeding rate ranging about 0.1 mL/minute to about 900 mL/minute.

13 . The process of claim 1 , wherein the TFF is conducted using a feeding pressure ranging from about 0.1 psi to about 90 psi.

14 . The process of claim 1 , wherein the TFF is conducted using a retentate pressure ranging from about 0.1 psi to about 90 psi.

15 . The process of claim 1 , wherein the TFF is conducted within a time ranging from about 10 minutes to about 9 hours for one production batch.

16 . The process of claim 1 , wherein the TFF is used to remove from about 50% to about 99.9999% of the non-membrane cellular or viral moiety.

17 . The process of claim 1 , wherein the TFF is used to concentrate and/or enrich the cellular or viral membrane from about 1 fold to about 100 fold.

18 . The process of claim 1 , which is used to prepare the cellular or viral membrane at a production rate ranging from about 1 g (measured as protein content)/hour to about 5 kg (measured as protein content)/hour for one production batch.

19 . The process of claim 1 , which is used to prepare the cellular membrane derived from a red blood cell.

20 . The process of claim 1 , which further comprises assessing a property of the cellular or viral membrane.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 23, 2022
From: GAO, WEIWEI; HU, CHE-MING JACK
To: ARYTHA BIOSCIENCES, LLC
Reel/Frame 059990/0143 →
Continuity (3)
Division 15777208
Provisional Application 62257161 · Nov 18, 2015
Related Publication 20220372234A1 · Nov 24, 2022
References Cited (42)
US 5490937A · van Reis · 1996 [cited by examiner]
US 8759294B2 · Egea et al. · 2014 [cited by applicant]
US 8889103B2 · Hay et al. · 2014 [cited by applicant]
US 11359058B2 · Gao et al. · 2022 [cited by applicant]
US 20130037977A1 · Burke et al. · 2013 [cited by applicant]
US 20130337066A1 · Zhang et al. · 2013 [cited by applicant]
US 20140256818A1 · Leung et al. · 2014 [cited by applicant]
US 20150343332A1 · Boyd et al. · 2015 [cited by applicant]
US 20170000875A1 · Hu · 2017 [cited by applicant]
US 20220380556A1 · Gao et al. · 2022 [cited by applicant]
CN 103857387A · 2014 [cited by applicant]
CN 108699253B · 2022 [cited by applicant]
HK 1261375B · 2022 [cited by applicant]
WO WO2013052167A2 · 2013 [cited by examiner]
Fang, et al. (2014) “Cancer Cell Membrane-Coated Nanoparticles for Anticancer Vaccination and Drug Delivery”, NanoLetters, 14: 2181-88. [cited by examiner]
Valencia, et al. (2010) “Single-Step Assembly by Homogenous Lipid-Polymeric and Lipid-Quantum Dot Nanoparticles Enables by Microfluidic Rapid Mixing”, ACS Nano, 4(3): 1671-79. (Year: 2010). [cited by examiner]
U.S. Appl. No. U.S. Appl. No. 15/777,208; Restriction Requirement dated Jul. 8, 2020. [cited by applicant]
U.S. Appl. No. U.S. Appl. No. 15/777,208; Response to Restriction Requirement dated Nov. 9, 2020. [cited by applicant]
U.S. Appl. No. U.S. Appl. No. 15/777,208; Non-Final Office Action dated Dec. 10, 2020. [cited by applicant]
U.S. Appl. No. U.S. Appl. No. 15/777,208; Response to Non-Final Office Action dated May 10, 2021. [cited by applicant]
U.S. Appl. No. U.S. Appl. No. 15/777,208; Final Office Action dated Jul. 8, 2021. [cited by applicant]
U.S. Appl. No. U.S. Appl. No. 15/777,208; Response to the Final Office Action dated Jan. 6, 2022. [cited by applicant]
U.S. Appl. No. U.S. Appl. No. 15/777,208; Notice of Allowance dated Feb. 17, 2022. [cited by applicant]
U.S. Appl. No. U.S. Appl. No. 17/836,571; Non-Final Office Action dated Jan. 30, 2025. [cited by applicant]
U.S. Appl. No. U.S. Appl. No. 17/836,571; Response to Non-Final Office Action dated Apr. 29, 2025. [cited by applicant]
U.S. Appl. No. U.S. Appl. No. 17/836,571; Final Office Action dated May 21, 2025. [cited by applicant]
U.S. Appl. No. U.S. Appl. No. 17/836,571; Response to the Final Office Action dated Aug. 20, 2025. [cited by applicant]
U.S. Appl. No. U.S. Appl. No. 17/836,571; Notice of Allowance dated Sep. 11, 2025. [cited by applicant]
Dalwadi, et al. (2005) “Comparison of Diafiltration and Tangential Flow Filtration for Purification of Nanoparticle Suspensions”, Pharmaceutical Research, 22(12): 2152-62. (Year: 2005). [cited by applicant]
Response to 2nd Office Action for Chinese patent application CN201680078779.6, dated Jul. 27, 2021, 27 pages. [cited by applicant]
Supplemental Amendments to 2nd Office Action for Chinese patent application CN201680078779.6, dated Sept. 23, 2021, 26 pages. [cited by applicant]
2nd Supplemental Response to 2nd Office Action for Chinese patent application CN201680078779.6, dated Oct. 12, 2021, 26 pages. [cited by applicant]
Notice of Registration Procedures for Chinese patent application CN201680078779.6, dated Oct. 25, 2021, 2 pages. [cited by applicant]
Notice to Grant the Patent Right for Chinese patent application CN201680078779.6, dated Oct. 25, 2021, 2 pages. [cited by applicant]
Search Report for Chinese patent application CN201680078779.6, dated Jun. 15, 2020, 2 pages. [cited by applicant]
1st Office Action for Chinese patent application CN201680078779.6, dated Jun. 29, 2020, 10 pages with extra 6 pages of English language equivalent or summary. [cited by applicant]
International Search Report for international patent application PCT/US2016/062935 (WO2017087897), dated Feb. 6, 2017, 3 pages. [cited by applicant]
Written Opinion of the International Searching Authority for international patent application PCT/US2016/062935 (WO2017087897), dated Feb. 6, 2017, 6 pages. [cited by applicant]
International Preliminary Report on Patentability for international patent application PCT/US2016/062935 (WO2017087897), dated May 22, 2018, 7 pages. [cited by applicant]
Response to 1st Office Action for Chinese patent application CN2016800787796, dated Jan. 14, 2021, 31 pages. [cited by applicant]
Claim Amendments (marked-up version) in Response to 1st Office Action for Chinese patent application CN2016800787796, dated Jan. 14, 2021, 16 pages. [cited by applicant]
2nd Office Action for Chinese patent application CN201680078779.6, dated May 14, 2021, 3 pages with extra 5 pages of English language equivalent or summery. [cited by applicant]